Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

STXS US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Stereotaxis, Inc.(STXS US)

$0.95+0.067.26%Ext:$0.88-0.066.63%(Market Closed · 01:00:03 UTC)
Ask AI
ProfileEntity StructureAll DocumentsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

STXS US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Stereotaxis, Inc.(STXS US)

$0.95+0.067.26%Ext:$0.88-0.066.63%(Market Closed · 01:00:03 UTC)
Ask AI
ProfileEntity StructureAll DocumentsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
All Documents

Financials & Metrics

FinancialsChartingShort InterestEmployees
All Documents

Financials & Metrics

FinancialsChartingShort InterestEmployees

Stereotaxis, Inc. — Company Profile

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UA
CEO
David L. Fischel
Headquarters
St. Louis, MO, US
IPO Date
Aug 12, 2004
Employees
131
Website
www.stereotaxis.com

Key Metrics

Price
$1.18
Market Cap
$115.56M
Revenue (TTM)
$6.29M
Net Income (TTM)
$-5861000.00
EPS (TTM)
-0.06
P/E (TTM)
-5.33
P/B (TTM)
5.90
Dividend Yield
0.00%
ROE (TTM)
-29.91%
ROA (TTM)
-10.85%
Operating Margin
-82.36%
Beta
1.27

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.

Website
www.stereotaxis.com
Location
St. Louis, MO, US
Phone314 678 6100
Employees131
CEODavid L. Fischel
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateAug 12, 2004

Latest Documents

SEC Filings(1.5K)

Expand
  • Form 4Benfer David18 Nov
  • Form 4Menawat Arun Swarup18 Nov
  • Form 4Isaac Paul J18 Nov
  • SC 13D/AStereotaxis, Inc.12 Nov
  • Form 4Ghodsian Fariba Fischel12 Nov
  • Form 4Fischel Nathan12 Nov
  • 8-KEntry into a Material Definitive Agreement10 Nov
  • SC 13GStereotaxis, Inc.19 Aug
  • EFFECTNotice of effectiveness14 Aug
  • EFFECTNotice of effectiveness14 Aug
  • 424B3Prospectus filing (Rule 424(b)(3))13 Aug
  • 424B3Prospectus filing (Rule 424(b)(3))13 Aug
  • 10-QQ2ended 30 Jun 202612 Aug
  • 8-KResults of Operations and Financial Condition11 Aug
  • 8-KOther Events15 Jul
  • S-3Registration statement (primary offering)15 Jul
  • S-3Registration statement (primary offering)15 Jul
  • 8-KUnregistered Sales of Equity Securities9 Jul
  • Form 4SHAMIR NACHUM1 Jul
  • Form 4Benfer David1 Jul

News

  • What Stereotaxis (STXS) Said on Its Q3 Earnings Call11 Nov
  • Stereotaxis, Inc. (STXS) Q3 2026 Earnings Call Transcript11 Nov
  • Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates10 Nov
  • Stereotaxis Announces Convertible Note Financing of Up To $24 Million10 Nov
  • First-in-Human Coronary Intervention Study Results of Robocath's Next-Generation Robotic System Highlighted at TCT2 Nov
  • Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology30 Oct
  • Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia22 Oct
  • Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 202620 Oct
  • Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society's HRX 202616 Sep
  • University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program3 Sep

Mentions in Filings

  • … r in New Mexico. Dr. Curet has served as a member of the board of directors of Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on obstructive sleep apnea, since December 2023, and of <strong>Stereotaxis, Inc.</strong> (NYSE American: STXS), a robotic technology company for the treatment of cardiac arrhythmias, since July 2021. She previously served as a director of Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company, f …
    Mobia Medical, Inc.Stereotaxis, Inc.·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q3 26·3 Aug
  • … ing following the sale of our bioprocessing analytics portfolio to Repligen. The compensation committee (1) removed Akoya Biosciences Inc., Apyx Medical Corporation, Bionano Genomics, Inc., Castle Biosciences, Inc., <strong>Stereotaxis, Inc.</strong>, Surmodidcs, Inc. and Zynex, Inc., and (2) added Cytek Biosciences, Inc., Frequency Electronics, Inc., Kopin Corporation, Ouster, Inc. and SoundThinking, Inc. This new 2026 peer group of seventeen (17) companies will …
    908 Devices Inc.Stereotaxis, Inc.·DEF 14A - Definitive proxy statement·Q2 26·29 Apr
  • … ort customer training and case usage. Internationally, our products are sold through distributors, supported by one full-time contracted sales consultant. We previously entered into a joint marketing agreement with <strong>Stereotaxis, Inc.</strong> The parties agreed to terminate the agreement in December 2024. Outside the U.S., we will continue to foster additional key partner relationships with distributors who will market, sell and support our products. 10 …
    Catheter Precision, Inc.Stereotaxis, Inc.·10-K - Annual report FY 2025·FY25·31 Mar
  • … 21. Additionally, Mr. Shamir has served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien (now Medtronic) in 2014. Mr. Shamir currently serves on the Board of Directors of <strong>Stereotaxis</strong> (NYSE: STXS) and SSI Diagnostica, a private-equity owned diagnostics company. Mr. Shamir holds a Bachelor of Science degree from the Hebrew University of Jerusalem and a Master of Public Administration from Harvard Univ
    MediWound Ltd.Stereotaxis, Inc.·EX-99.1 - 6-K - EXHIBIT 99.1·Q1 26·30 Mar
  • ?
    March 18, 2026 David L. Fischel Chief Executive Officer <strong>Stereotaxis, Inc.</strong> 710 North Tucker Boulevard, Suite 110 St. Louis, Missouri 63101 Re: Stereotaxis, Inc. Registration Statement on Form S-3 Filed March 13, 2026 File No. 333-294288 Dear David L. Fischel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that …
    Stereotaxis, Inc.·LETTER - UPLOAD - Filing review upload·18 Mar·18 Mar
  • ?
    March 18, 2026 David L. Fischel Chief Executive Officer <strong>Stereotaxis, Inc.</strong> 710 North Tucker Boulevard, Suite 110 St. Louis, Missouri 63101 Re: Stereotaxis, Inc. Registration Statement on Form S-3 Filed March 13, 2026 File No. 333-294288 Dear David L. Fischel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you …
    Stereotaxis, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·18 Mar·18 Mar

Key Stats

Trading

Px/Chg 1D$1.18 / -1.67%
Prev Close$1.39
% of 52Wk H38.72%
Avg Volume429.16K
Beta1.27
Mkt Cap115.56M
FD Mkt Cap136.13M

Float

Shrs Out/Float97.93M / 69.58M
Short Float0.06%
Days to Cover6.13
Stock Repurchased$0.00

Current Valuation

EV111.47M
EV/EBITDA-5.55
EV/Sales3.57
P/B5.90
P/S3.70
FCF Yield-3.05%
ROE-29.91%
ROA-10.85%
Current Ratio1.55

Estimates

P/E-5.33
Est P/E0.00
Est EPS-0.04
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-15.15-7.24-8.14-7.33-33.31-19.72
Price / Sales11.454.706.306.5521.3218.37
Price / Book Value8.604.157.6915.429.845.90
Price / Free Cash Flow-25.82-12.26-17.75-20.67-45.62-32.82
ENTERPRISE VALUE METRICS
Enterprise Value152.7135.2159.9175.5181.5111.5
Enterprise Value / Sales11.204.805.976.5221.0017.72
Enterprise Value / EBITDA-15.60-7.37-7.53-7.38-35.34-20.39
Enterprise Value / EBIT-14.69-7.20-7.32-7.09-32.82-19.02

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-1.9%35.028.126.826.932.4
Gross Income-7.4%23.218.514.914.617.1
EBITDA12%-12.8-18.3-21.2-23.8-20.1
EBIT13.8%-12.9-18.8-21.8-24.7-21.6
Net Income19.2%-10.7-18.3-20.7-24.0-21.6
EPS (Diluted)11.8%-0.16-0.26-0.27-0.30-0.25
BALANCE SHEET
Cash & ST Inv-23.3%38.728.419.812.213.4
Total Assets-3.8%61.053.441.946.752.3
Total Liabilities11.7%21.621.520.035.333.5
Total Shareholder Equity-17%39.431.921.911.418.7
CASH FLOW
Net Operating Cash Flow46.8%-2.9-8.4-9.1-8.5-13.7
Cap Ex-49.2%-1.4-2.4-0.4-0.0-0.1
Free Cash Flow33.5%-4.3-10.8-9.5-8.5-13.8

Enterprise Value Bridge

Millions USD18 Nov '26
Price (As of 18 Nov '26)0.95
Basic Shares97.93
Market Cap92.7
Diluted Shares100.03
Fully Diluted Shares Outstanding100.03
Fully Diluted Market Cap94.7
+Consolidated Debt5.2
−In-the-Money Convertible Debt—
+Capital Leases5.2
+Operating Leases—
−Cash & Equivalents-10.5
−Short-term Investments-
+Total Preferred5.2
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value92.7

Segment data

Revenue

by Products and services

  • Disposables Service And Accessories68%
  • Systems32%

Revenue

by Geography

  • Non-us60%
  • United States40%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

Stereotaxis, Inc. — Company Profile

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UA
CEO
David L. Fischel
Headquarters
St. Louis, MO, US
IPO Date
Aug 12, 2004
Employees
131
Website
www.stereotaxis.com

Key Metrics

Price
$1.18
Market Cap
$115.56M
Revenue (TTM)
$6.29M
Net Income (TTM)
$-5861000.00
EPS (TTM)
-0.06
P/E (TTM)
-5.33
P/B (TTM)
5.90
Dividend Yield
0.00%
ROE (TTM)
-29.91%
ROA (TTM)
-10.85%
Operating Margin
-82.36%
Beta
1.27

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.

Website
www.stereotaxis.com
Location
St. Louis, MO, US
Phone314 678 6100
Employees131
CEODavid L. Fischel
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateAug 12, 2004

Latest Documents

SEC Filings(1.5K)

Expand
  • Form 4Benfer David18 Nov
  • Form 4Menawat Arun Swarup18 Nov
  • Form 4Isaac Paul J18 Nov
  • SC 13D/AStereotaxis, Inc.12 Nov
  • Form 4Ghodsian Fariba Fischel12 Nov
  • Form 4Fischel Nathan12 Nov
  • 8-KEntry into a Material Definitive Agreement10 Nov
  • SC 13GStereotaxis, Inc.19 Aug
  • EFFECTNotice of effectiveness14 Aug
  • EFFECTNotice of effectiveness14 Aug
  • 424B3Prospectus filing (Rule 424(b)(3))13 Aug
  • 424B3Prospectus filing (Rule 424(b)(3))13 Aug
  • 10-QQ2ended 30 Jun 202612 Aug
  • 8-KResults of Operations and Financial Condition11 Aug
  • 8-KOther Events15 Jul
  • S-3Registration statement (primary offering)15 Jul
  • S-3Registration statement (primary offering)15 Jul
  • 8-KUnregistered Sales of Equity Securities9 Jul
  • Form 4SHAMIR NACHUM1 Jul
  • Form 4Benfer David1 Jul

News

  • What Stereotaxis (STXS) Said on Its Q3 Earnings Call11 Nov
  • Stereotaxis, Inc. (STXS) Q3 2026 Earnings Call Transcript11 Nov
  • Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates10 Nov
  • Stereotaxis Announces Convertible Note Financing of Up To $24 Million10 Nov
  • First-in-Human Coronary Intervention Study Results of Robocath's Next-Generation Robotic System Highlighted at TCT2 Nov
  • Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology30 Oct
  • Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia22 Oct
  • Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 202620 Oct
  • Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society's HRX 202616 Sep
  • University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program3 Sep

Mentions in Filings

  • … r in New Mexico. Dr. Curet has served as a member of the board of directors of Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on obstructive sleep apnea, since December 2023, and of <strong>Stereotaxis, Inc.</strong> (NYSE American: STXS), a robotic technology company for the treatment of cardiac arrhythmias, since July 2021. She previously served as a director of Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company, f …
    Mobia Medical, Inc.Stereotaxis, Inc.·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q3 26·3 Aug
  • … ing following the sale of our bioprocessing analytics portfolio to Repligen. The compensation committee (1) removed Akoya Biosciences Inc., Apyx Medical Corporation, Bionano Genomics, Inc., Castle Biosciences, Inc., <strong>Stereotaxis, Inc.</strong>, Surmodidcs, Inc. and Zynex, Inc., and (2) added Cytek Biosciences, Inc., Frequency Electronics, Inc., Kopin Corporation, Ouster, Inc. and SoundThinking, Inc. This new 2026 peer group of seventeen (17) companies will …
    908 Devices Inc.Stereotaxis, Inc.·DEF 14A - Definitive proxy statement·Q2 26·29 Apr
  • … ort customer training and case usage. Internationally, our products are sold through distributors, supported by one full-time contracted sales consultant. We previously entered into a joint marketing agreement with <strong>Stereotaxis, Inc.</strong> The parties agreed to terminate the agreement in December 2024. Outside the U.S., we will continue to foster additional key partner relationships with distributors who will market, sell and support our products. 10 …
    Catheter Precision, Inc.Stereotaxis, Inc.·10-K - Annual report FY 2025·FY25·31 Mar
  • … 21. Additionally, Mr. Shamir has served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien (now Medtronic) in 2014. Mr. Shamir currently serves on the Board of Directors of <strong>Stereotaxis</strong> (NYSE: STXS) and SSI Diagnostica, a private-equity owned diagnostics company. Mr. Shamir holds a Bachelor of Science degree from the Hebrew University of Jerusalem and a Master of Public Administration from Harvard Univ
    MediWound Ltd.Stereotaxis, Inc.·EX-99.1 - 6-K - EXHIBIT 99.1·Q1 26·30 Mar
  • ?
    March 18, 2026 David L. Fischel Chief Executive Officer <strong>Stereotaxis, Inc.</strong> 710 North Tucker Boulevard, Suite 110 St. Louis, Missouri 63101 Re: Stereotaxis, Inc. Registration Statement on Form S-3 Filed March 13, 2026 File No. 333-294288 Dear David L. Fischel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that …
    Stereotaxis, Inc.·LETTER - UPLOAD - Filing review upload·18 Mar·18 Mar
  • ?
    March 18, 2026 David L. Fischel Chief Executive Officer <strong>Stereotaxis, Inc.</strong> 710 North Tucker Boulevard, Suite 110 St. Louis, Missouri 63101 Re: Stereotaxis, Inc. Registration Statement on Form S-3 Filed March 13, 2026 File No. 333-294288 Dear David L. Fischel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you …
    Stereotaxis, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·18 Mar·18 Mar

Key Stats

Trading

Px/Chg 1D$1.18 / -1.67%
Prev Close$1.39
% of 52Wk H38.72%
Avg Volume429.16K
Beta1.27
Mkt Cap115.56M
FD Mkt Cap136.13M

Float

Shrs Out/Float97.93M / 69.58M
Short Float0.06%
Days to Cover6.13
Stock Repurchased$0.00

Current Valuation

EV111.47M
EV/EBITDA-5.55
EV/Sales3.57
P/B5.90
P/S3.70
FCF Yield-3.05%
ROE-29.91%
ROA-10.85%
Current Ratio1.55

Estimates

P/E-5.33
Est P/E0.00
Est EPS-0.04
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-15.15-7.24-8.14-7.33-33.31-19.72
Price / Sales11.454.706.306.5521.3218.37
Price / Book Value8.604.157.6915.429.845.90
Price / Free Cash Flow-25.82-12.26-17.75-20.67-45.62-32.82
ENTERPRISE VALUE METRICS
Enterprise Value152.7135.2159.9175.5181.5111.5
Enterprise Value / Sales11.204.805.976.5221.0017.72
Enterprise Value / EBITDA-15.60-7.37-7.53-7.38-35.34-20.39
Enterprise Value / EBIT-14.69-7.20-7.32-7.09-32.82-19.02

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-1.9%35.028.126.826.932.4
Gross Income-7.4%23.218.514.914.617.1
EBITDA12%-12.8-18.3-21.2-23.8-20.1
EBIT13.8%-12.9-18.8-21.8-24.7-21.6
Net Income19.2%-10.7-18.3-20.7-24.0-21.6
EPS (Diluted)11.8%-0.16-0.26-0.27-0.30-0.25
BALANCE SHEET
Cash & ST Inv-23.3%38.728.419.812.213.4
Total Assets-3.8%61.053.441.946.752.3
Total Liabilities11.7%21.621.520.035.333.5
Total Shareholder Equity-17%39.431.921.911.418.7
CASH FLOW
Net Operating Cash Flow46.8%-2.9-8.4-9.1-8.5-13.7
Cap Ex-49.2%-1.4-2.4-0.4-0.0-0.1
Free Cash Flow33.5%-4.3-10.8-9.5-8.5-13.8

Enterprise Value Bridge

Millions USD18 Nov '26
Price (As of 18 Nov '26)0.95
Basic Shares97.93
Market Cap92.7
Diluted Shares100.03
Fully Diluted Shares Outstanding100.03
Fully Diluted Market Cap94.7
+Consolidated Debt5.2
−In-the-Money Convertible Debt—
+Capital Leases5.2
+Operating Leases—
−Cash & Equivalents-10.5
−Short-term Investments-
+Total Preferred5.2
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value92.7

Segment data

Revenue

by Products and services

  • Disposables Service And Accessories68%
  • Systems32%

Revenue

by Geography

  • Non-us60%
  • United States40%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN